CARMELINA Neutral on CV and Renal Outcomes; No Increased hHF Risk

BI/Lilly presented data from CARMELINA, the Tradjenta CV and renal outcomes study (press release). Unsurprisingly, the trial failed to demonstrate superiority for either CV or renal composite endpoints. Of note, there was no increased risk of hospitalization for heart failure with Tradjenta. Below, FENIX provides thoughts on the neutral CARMELINA result.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.